FDA Drafts New Guidance on Drug Container Closures

FDA on 14 August 2026 announced a draft guidance rewriting how it expects sponsors to evaluate the container closure systems (CCSs) that package human drugs and biological products — the vials, syringes, cartridges, and their stoppers, seals, and delivery-device parts that stand between a formulation and contamination, degradation, or dosing error. The draft is meant to replace FDA’s 1999 guidance on the same subject, and it arrives eleven days after a narrower, biosimilar-specific companion document covering much of the same ground.

What the guidance covers

The draft sets out guiding principles for evaluating the quality of container closure systems used to package drugs and biological products for human use. Its scope explicitly reaches two overlapping categories: CCSs that are themselves device constituent parts of a combination product — a prefilled syringe or autoinjector, for instance — and CCSs used to package the drug or biological product constituent part of a combination product. FDA states the guidance applies to applications, including amendments and supplements to already-approved applications, for both standalone drug and biological products and combination products, regardless of whether the lead center is CDER, CBER, or CDRH.

A general description of the full presentation — the complete packaged product a patient or provider handles — is expected in the chemistry, manufacturing, and controls (CMC) section of an application, with complete CMC information required for the proposed container closure system and any device constituent parts. That is a broader ask than the 1999 guidance made, which predates the current volume of prefilled and device-integrated drug products on the market.

The risk-based framework

• The draft lists factors sponsors should weigh when assessing whether a CCS is suitable for its intended use, oriented around protection of the product, compatibility with it, and consistent performance over the product's shelf life.
• FDA signals it will issue topic-specific follow-on guidances addressing narrower questions — among them, methods for evaluating and characterizing novel container closure systems, and recommendations for extractables and leachables evaluations and the toxicological risk assessments that follow from them.
• The document is framed as a general foundation: sponsors should expect this guidance to be read alongside, not instead of, the topic-specific guidances still to come.

A companion guidance for biosimilars, eleven days earlier

The 14 August draft did not arrive in isolation. On 3 August, FDA issued a separate draft guidance, “Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts,” aimed specifically at applicants developing CCSs and device constituent parts — prefilled syringes, autoinjectors, pen injectors — for proposed biosimilar and interchangeable biosimilar products. FDA says that guidance fulfills a commitment made under the Biosimilar User Fee Act (BsUFA III) and expands on recommendations in earlier FDA guidance on delivery devices. Comments on the biosimilar-specific draft are due 2 October 2026, eleven days ahead of the general guidance's own comment deadline.

Read together, the two drafts describe a general CCS framework meant to anchor a family of more specific guidances that follow it — a structure FDA has used elsewhere in CMC policy, publishing a foundational document first and layering topic-specific recommendations on top rather than issuing one exhaustive guidance.